Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

about

Cardiac Actions of a Small Molecule Inhibitor Targeting GATA4-NKX2-5 Interaction.

P2860

Q55334799-477B7772-D708-4EE8-996F-AEFF7F54A5AA

P2860

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Item

http://www.wikidata.org/entity/Q50259289

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

@en

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

@nl

type

Item

label

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

@en

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

@nl

prefLabel

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

@en

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

@nl

P1476

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy

@en

P2093

Arnold S Baas

http://www.w3.org/2001/XMLSchema#string

Daniel J Philipson

http://www.w3.org/2001/XMLSchema#string

Eugene C DePasquale

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis

Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence

Targets for therapy in sarcomeric cardiomyopathies

Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes

Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity

Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy

Cardiac hypertrophy: the good, the bad, and the ugly

Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair.

Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.

P2888

s10741-017-9648-x

P304

879-888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10741-017-9648-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric H. Yang

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28856513

http://www.w3.org/2001/XMLSchema#string

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

about

P2860

P2860

Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698